News

Theranexus shares update of Phase 1/2 trial of Batten-1

Treatment for up to six months with Batten-1 — Theranexus’ novel therapy for juvenile Batten disease — reduced nerve cell death and stabilized patients’ motor symptoms. That’s according to preliminary results from an ongoing Phase 1/2 clinical trial testing the experimental therapy. The results will be presented at the…

Advocates go global this June 9 for Batten Awareness Day

From sharing stories on social media — using hashtags like #BattenDay2023 and #BattenAdvocatesForACure — to wearing something orange this June 9 to participating in a 5K fundraising challenge, supporters globally are poised to mark this year’s International Batten Disease Awareness Day. Observed annually, the June 9 Awareness Day calls attention…